-
Mashup Score: 7Acute myeloid leukemia management and research in 2025 - 9 hour(s) ago
The first 5 decades of research in acute myeloid leukemia (AML) were dominated by the cytarabine plus anthracyclines backbone, with advances in strategies including allogeneic hematopoietic stem cell…
Categories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Speaker: Maximilian Stahl Dr. Stahl graduated from Hannover Medical School in Hannover, Germany. He received his internal medicine residency training at the Yale School of Medicine where he also served as a chief medical resident. He then completed his Hematology and Oncology fellowship training at the Memorial Sloan Kettering Cancer Center in New York City. He is currently a member of the Adult Leukemia Group at Dana-Farber Cancer Institute and also a member of the faculty at Harvard Medical School.
Source: us06web.zoom.usCategories: General Medicine News, Hem/OncsTweet-
RT @TheIACH: Join us TODAY at 6PM CET 📌Post #ASH24 Webinar Dedicated to AML Register for FREE https://t.co/zsKkS1oGJ6 @MaxStahlMD @Mohty…
-
-
Mashup Score: 5
Speaker: Maximilian Stahl Dr. Stahl graduated from Hannover Medical School in Hannover, Germany. He received his internal medicine residency training at the Yale School of Medicine where he also served as a chief medical resident. He then completed his Hematology and Oncology fellowship training at the Memorial Sloan Kettering Cancer Center in New York City. He is currently a member of the Adult Leukemia Group at Dana-Farber Cancer Institute and also a member of the faculty at Harvard Medical School.
Source: us06web.zoom.usCategories: General Medicine News, Hem/OncsTweet-
RT @TheIACH: Join us TODAY at 6PM CET 📌Post #ASH24 Webinar Dedicated to AML Register for FREE https://t.co/zsKkS1oGJ6 @MaxStahlMD @Mohty…
-
-
Mashup Score: 1Clinical Characteristics and Outcomes of CCUS With ZRSR2 Mutations | Blood Cancers Today - 2 day(s) ago
ZRSR2 mutations in clonal cytopenia correlated with gender, with a significant subset showing concurrent hematologic malignancies or chromosomal abnormalities.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
A study presented at #ASH24 by Mahmoud Yacout, MD (@MayoCancerCare) outlined the clinical characteristics and outcomes of clonal cytopenia of undetermined significance (CCUS) with ZRSR2 mutations. 📰 Read more: https://t.co/x6ZxLFBW6N https://t.co/j6hhQdq8dp
-
-
Mashup Score: 2Hematology With Afaf E. Osman, MD - 4 day(s) ago
Dr. Osman is an assistant professor at the University of Utah Huntsman Cancer Institute where she treats myeloid malignancies. Her research interest is in myeloid precursor conditions including clonal hematopoiesis.
Source: mashupmd.comCategories: General Medicine News, General HCPsTweet-
New therapeutic targets in MDS were highlighted at #ASH24, with promising early-phase trials for Elritecept, R289, Vibectomab, and DVF890. @AfafOsman7 is optimistic about these developments offering new hope for MDS patients in 2025. 👉Read more: https://t.co/p0YYVBanSc https://t.co/6DzeD3bT5x
-
-
Mashup Score: 1Ziftomenib, Venetoclax, Azacitidine in Pediatric Relapsed or Refractory Acute Leukemia | Blood Cancers Today - 6 day(s) ago
Ziftomenib plus venetoclax, and azacitidine in pediatric patients with KMT2A-rearranged, NPM1-mutated, or NUP98-rearranged acute leukemias is being evaluated in phase 1 trial.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
The phase 1 ZiVA trial will evaluate the combination of ziftomenib, venetoclax, and azacitidine in pediatric patients with KMT2A-r, NPM1-m or NUP98-r acute leukemias. The study's design was presented at #ASH24 by David McCall, MD, of @MDAndersonNews. ➡️ https://t.co/dcAXyxJgbN https://t.co/lItD1slau7
-
-
Mashup Score: 1ASH Clinical News: January 2025 From the Desk Of... - 8 day(s) ago
Editor-in-Chief Aaron Gerds, MD, previews what’s to come in ASH Clinical News. In the January edition, learn how the recent overturning of the Chevron doctri…
Source: www.youtube.comCategories: General Medicine News, Oncologists1Tweet-
Hear from Editor-in-Chief @AaronGerds, MD, as he previews the January edition of @ASHClinicalNews 🩸 ➡️ https://t.co/0X235xXQCa Highlights include #ASH24 on location meeting coverage of innovative and significant abstracts and more! @ASH_hematology
-
-
Mashup Score: 25
Speaker: Ali Bazarbachi Ali Bazarbachi, MD, PhD is a Professor of Medicine (Hematology and Oncology), Professor of Anatomy, Cell Biology and Physiological Sciences, and Founding Director of the bone marrow transplantation program at the American University of Beirut-Medical Center. He received his MD and PhD degrees, residency and fellowship training at the University of Paris in France. Dr. Ali Bazarbachi’s basic and translational research focuses on targeted therapies for hematological malignancies as well as post-transplant pharmacological interventions. He has co-authored more than 400 articles in leading scientific journals including The New England Journal of Medicine, Science, Journal of Experimental Medicine, The Lancet Oncology, Journal of Clinical Oncology, Blood, Nature Communication, and Cancer Research. He is the Chairman of the EBMT Lymphoma Working Party, a cofounder of the International Academy for Clinical Hematology, past President and current Secretary General of the
Source: us06web.zoom.usCategories: General Medicine News, Hem/OncsTweet-
Don’t miss the latest lymphoma studies presented at #ASH24 Free registration at: https://t.co/FhMOTatFUL @TheIACH @AssoELLyE @LLSusa @lymphomahub @knowyournodes @LymphomaAction @lymphoma @LAL_NI @TheEBMT_CTIWP https://t.co/bz2YHEi9ia
-
-
Mashup Score: 0Acalabrutinib/BR Benefit Extends to High-Risk Subgroups of Previously Untreated MCL | Blood Cancers Today - 11 day(s) ago
A significant reduction in the risk of disease progression or death resulted from treatment with acalabrutinib combined with BR in patients with previously untreated MCL.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
Read more about the ECHO trial, presented at #ASH24 by Martin Dreyling, MD, of @LMU_Muenchen, that led to the approval. ➡️➡️ https://t.co/yRLzyB7pXs https://t.co/IZJ7W52FIP
-
-
Mashup Score: 3Addressing Racial Disparities in Stress and Coping for Indolent Blood Cancers | Blood Cancers Today - 12 day(s) ago
A study stresses psychological support as an essential component of comprehensive cancer care.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
📝 A study presented at #ASH24 by @woke_T_cell_MD, of @FoxChaseCancer, explored racial disparities in cancer-related stress and coping strategies among patients with indolent blood cancers undergoing active observation. ➡️ Read more: https://t.co/3GlfazQUJG https://t.co/HKjY8FwjDe
-
Acute myeloid leukemia therapy has come a long way since being dominated by cytarabine and anthracyclines. @DrHKantarjian et al review the frontline and later line therapies in AML & discuss important research directions in this review. https://t.co/Vys7JCVfZF @OncoAlert #ASH24 https://t.co/lZIWY7sOps